Please assess the completion status of the following clinical trial:

Trial Title: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Participants with a relapsing form of multiple sclerosis (RMS) having signed written informed consent.~Exclusion criteria:~* According to local labelling,~* Less than 18 years of age,~* Current or history of receiving teriflunomide,~* Previous treatment with leflunomide within 6 months prior to baseline,~* Participants with preexisting acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) greater than 2 times the upper limit of normal (ULN),~* Known history of active tuberculosis (TB) or latent TB infection, either diagnosed by standard medical practice or guidelines (including skin or blood test, chest X-ray, or as appropriate per local practice),~* Known history of severe immunodeficiency, acquired immunodeficiency syndrome (AIDS), bone marrow disease, acute or severe active infections,~* Women who were pregnant or breast-feeding,~* Female participants with a positive pregnancy test at screening or women of child-bearing potential who did not agree to use reliable contraception throughout the course of the study,~* Male participants (only when required according to local labeling): unwilling to use reliable contraception during the course of the study,~* Additional exclusion criteria applicable for Europe (EU) countries (in accordance with contraindications of EU summary of product characteristics \[SmPC\]):~  * Participants with significantly impaired bone marrow function or significant anaemia, leukopenia, neutropenia or thrombocytopenia,~ * Participants with severe active infection until resolution,~ * Participants with severe renal impairment undergoing dialysis, because insufficient clinical experience was available in this participant group,~ * Participants with severe hypoproteinaemia, e.g. in nephrotic syndrome.~* Hypersensitivity to the active substance or to any of the excipients,~* Other additional contraindications per local labeling.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriflunomide (Type: EXPERIMENTAL): Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).